<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0007417'>Discoid lupus erythematosus</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLE</z:e>), the most common <z:e sem="disease" ids="C0409974" disease_type="Disease or Syndrome" abbrv="">lupus erythematosus</z:e> (LE)-specific <z:hpo ids='HP_0011010'>chronic</z:hpo> manifestation of the skin, is often resistant to therapy </plain></SENT>
<SENT sid="1" pm="."><plain><z:mpath ids='MPATH_127'>Atrophy</z:mpath>, <z:hpo ids='HP_0100699'>scarring</z:hpo>, and <z:hpo ids='HP_0001000'>pigmentation</z:hpo> are often observed </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we report two cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLE</z:e> that were successfully treated with tocoretinate, a compound containing a mixture of <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> and <z:chebi fb="1" ids="27013">tocopherol</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain><z:mpath ids='MPATH_127'>Atrophy</z:mpath> and <z:hpo ids='HP_0001000'>pigmentation</z:hpo> improved in both cases </plain></SENT>
<SENT sid="4" pm="."><plain>The mechanism of action of tocoretinate is discussed </plain></SENT>
</text></document>